Shannxi Linxin Biotechnology Co.,Ltd-Shannxi Linxin Biotechnology Co.,Ltd

Latest News Release

2015-03-11	API CHINA OF Guang Zhou
2014-03-11	Global Spending on Medicines to Increase 30% by 2018, to $1.3 Trillion
2015-03-02	The First Class of Biosimilars to Enter the US Market Will Generate $1.8 Billion by 2023
2015-03-11	Shaanxi LiXin Biotechnology Co., Ltd. to introduce the latest atomized extraction and separation technology
2015-03-11	Takeda Announces Transfer of License Agreement for Human Papillomavirus (HPV) Vaccine to Kaketsuken
2015-03-11	Takeda Announces Transfer of License Agreement for Human Papillomavirus (HPV) Vaccine to Kaketsuken

Information

2015-03-11	Novartis Cosentyx Receives Positive CHMP Opinion for First-Line Treatment of Moderate-to-Severe Psoriasis Patients
2015-03-11	Takeda Announces Transfer of License Agreement for Human Papillomavirus (HPV) Vaccine to Kaketsuken
2015-03-11	Takeda Announces Transfer of License Agreement for Human Papillomavirus (HPV) Vaccine to Kaketsuken
2015-03-11	Takeda Announces Transfer of License Agreement for Human Papillomavirus (HPV) Vaccine to Kaketsuken
2015-03-11	Takeda Announces Transfer of License Agreement for Human Papillomavirus (HPV) Vaccine to Kaketsuken
2015-03-11	Takeda Announces Transfer of License Agreement for Human Papillomavirus (HPV) Vaccine to Kaketsuken

Reports & Publications

Takeda Announces Transfer of License Agreement for Human Papillomavirus (HPV) Vaccine to Kaketsuken

Relationship with Society

Takeda Announces Transfer of License Agreement for Human Papillomavirus (HPV) Vaccine to Kaketsuken